Business
– Teva will pay $40 million for the lung disease drug developer and up to $125 million in milestone payments plus royalties. – –...
Hi, what are you looking for?
– Teva will pay $40 million for the lung disease drug developer and up to $125 million in milestone payments plus royalties. – –...
– Founder Roni Naftali / Tamar Matrfi – Eden Springs sold its operations and subsidiaries to funds affiliated with Rhone Capital. Mineral water producer...
– Eyal Waldman justified delisting from the TASE at an investors conference in London. – – /By Shmulik Shelach/ “The decision to delist from...
– – / Lital Istamati, London / “The Israeli economy has been making a lot of noise lately, but it is very positive. The...
– Property and Building bought the Barney’s building in 2011 for $122 million, and has made an 89% return on investment. – The Barney’s...
– TASE head of international sales Sharon Naveh told “Bloomberg.”: We may see this great disappointment reflected in the market. – – / By...
– Teva sold the sleeping pills in packaging for heart failure medication. – Photo: For Illustration only – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA)...
– Check Point co-founder, chairman and CEO Gil Shwed : “I work for the interest and the challenge”. – – / By Hagai Golan/ In...
– – Evogene Ltd. (TASE:EVGN) plans an offering on the New York Stock Exchange (NYSE). The company notified the Tel Aviv Stock Exchange today...
– – Direct foreign investment in Israel totaled $2.3 billion in April 2013, of which $2 billion was for the acquisition of 20% of Iscar...